Bioventus chose Bazis NN as its authorized distributor for DUROLANE® single-injection joint-fluid osteoarthritis (OA) treatment in Russia.
“We believe the OA market in Russia is underserved and the patients there will benefit greatly from DUROLANE,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Bazis has a terrific track record in marketing and selling orthopaedic solutions in Russia and we are pleased they are helping Bioventus reach more patients and physicians with our proven pain reliever for osteoarthritis.”
Bioventus chose Bazis NN as its authorized distributor for DUROLANE® single-injection joint-fluid osteoarthritis (OA) treatment in Russia.
“We believe the OA market in Russia is underserved and the patients there will benefit greatly from DUROLANE,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Bazis has a terrific track record...
Bioventus chose Bazis NN as its authorized distributor for DUROLANE® single-injection joint-fluid osteoarthritis (OA) treatment in Russia.
“We believe the OA market in Russia is underserved and the patients there will benefit greatly from DUROLANE,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Bazis has a terrific track record in marketing and selling orthopaedic solutions in Russia and we are pleased they are helping Bioventus reach more patients and physicians with our proven pain reliever for osteoarthritis.”
Copy to clipboard 
